The AstraZeneca (Wuxi) International Life Science Innovation Campus is launched in Wuxi, Jiangsu province on Sept 7. [Photo provided to chinadaily.com.cn]

AstraZeneca, a global biopharmaceutical giant, tapped into the potential of the intelligent medical industry by unveiling the AstraZeneca (Wuxi) International Life Science Innovation Campus in Wuxi, Jiangsu province on Sept 7.

The park, launched during the ongoing 2019 World Internet of Things Expo, is another attempt by AstraZeneca to build an incubation platform for early research and development, the industrialization of research achievements, displaying intelligent products, and professional services in the life science sector.

The British-Swedish pharmaceutical multinational has been in the Wuxi market for 26 years and signed an agreement with the Wuxi National Hi-Tech District in March in an attempt to attract top overseas medical and treatment enterprises, as well as research institutions, to propel the development of Wuxi's intelligent medical industry.

A leader in the pharmaceutical industry, AstraZeneca has always been committed to promoting "patient-centered" innovation. The new campus will help serve this goal and support AstraZeneca's transition from a traditional manufacturer of medicine to an innovative healthcare company, said Wang Lei, CEO of AstraZeneca China.

Wang added that Wuxi is at the forefront of AstraZeneca's effort to advance cross-border cooperation and create an innovation ecosystem.

Innovative companies from China and other countries, including Russia, the United Kingdom, and Sweden, have agreed to set up operations in the campus.

Newly-launched AstraZeneca (Wuxi) International Life Science Innovation Campus [Photo provided to chinadaily.com.cn]